Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Symic Bio raises $30mm in Series B round

Executive Summary

Symic Biomedical Inc. (therapeutics focused on matrix biology) raised $30mm in its Series B financing round that included participation from all existing major investors along with new investor HEDA Ventures. The company has raised over $73mm since its inception through a seed round, a two tranche series A round and the B round. Symic will use the proceeds from the financing to help fund a planned Phase III trial of clinical program SB030 for the prevention of peripheral vein graft failure and to support development of SB061 for pain management and disease modification in treating osteoarthritis of the knee.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies